Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Capital Leases: 2023-2025

Historic Capital Leases for bioAffinity Technologies (BIAF) over the last 2 years, with Sep 2025 value amounting to $1,998.

  • bioAffinity Technologies' Capital Leases fell 99.63% to $1,998 in Q3 2025 from the same period last year, while for Sep 2025 it was $1,998, marking a year-over-year decrease of 99.63%. This contributed to the annual value of $444,448 for FY2024, which is 46.80% down from last year.
  • Latest data reveals that bioAffinity Technologies reported Capital Leases of $1,998 as of Q3 2025, which was down 49.32% from $3,942 recorded in Q2 2025.
  • bioAffinity Technologies' Capital Leases' 5-year high stood at $929,570 during Q3 2023, with a 5-year trough of $1,998 in Q3 2025.
  • For the 3-year period, bioAffinity Technologies' Capital Leases averaged around $497,264, with its median value being $543,007 (2024).
  • Data for bioAffinity Technologies' Capital Leases shows a maximum YoY crashed of 99.63% (in 2025) over the last 5 years.
  • Over the past 3 years, bioAffinity Technologies' Capital Leases (Quarterly) stood at $835,467 in 2023, then tumbled by 46.80% to $444,448 in 2024, then slumped by 99.63% to $1,998 in 2025.
  • Its Capital Leases was $1,998 in Q3 2025, compared to $3,942 in Q2 2025 and $335,899 in Q1 2025.